Bavarian Nordic A/S (BAVA.CO)
| Previous Close | 221.10 |
| Open | 218.70 |
| Bid | 219.60 x 0 |
| Ask | 219.70 x 0 |
| Day's Range | 215.60 - 222.30 |
| 52 Week Range | 125.55 - 300.00 |
| Volume | |
| Avg. Volume | 720,371 |
| Market Cap | 17.6B |
| Beta (5Y Monthly) | 1.53 |
| PE Ratio (TTM) | 24.41 |
| EPS (TTM) | 9.00 |
| Earnings Date | Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 267.29 |
ZacksBavarian Nordic (BVNRY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Bavarian Nordic (BVNRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
GlobeNewswireBavarian Nordic Upgrades its Financial Guidance for 2024
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, combined with improved performance in Travel Health, as well as other parts of the business, Bavarian Nordic now expects revenue between DKK 5,400 million and DKK 5,800 million and EBITDA between DKK 1,450 million and DKK 1,700 million. Revenue from the Travel Health business is now expected at approximate
- GlobeNewswire
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak. Under the agreement, UNICEF will procure 1 million doses of the vaccine which includes the 500,000 doses that were committed by Gavi and announced on September 18, 2024. As pa
